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In this issue of Cell Stem Cell, Nakamura et al. (2014) use human pluripotent stem cells to generate immor-
talized megakaryocyte progenitor cell lines that can be cryopreserved, expanded in vitro, and induced to
undergo terminal maturation and platelet release. This strategy advances efforts to produce clinically rele-
vant numbers of tissue-culture-derived platelets for transfusion therapies.Platelets are a central component of the
blood clotting system. Many diseases
and modern medical treatments cause
reduced platelet numbers (thrombocyto-
penia), so demands for transfusions of
these cells are on the rise. Current hu-
man-donor-derived platelets are limited
in supply, have a short shelf life, and pre-
sent infectious risks related to donor
transmission or the requirement for room
temperature storage, which promotes
bacterial proliferation. In vitro hematopoi-
etic differentiation of human pluripotent
stem cells (PSCs), including induced
pluripotent stem cells and embryonic
stem cells, represents a potential new
source of megakaryocytes (Mks) and
platelets for transfusion therapies. In prin-
ciple, it should be possible to manufac-
ture unlimited PSC-derived supplies of
platelets with robust biological activity
and a long circulating half-life. Two chal-
lenges exist in this field, both of which
are addressed in this issue of Cell Stem
Cell byNakamura et al. (2014): (1) the gen-
eration of Mks and their platelet progeny
from pluripotent stem cells is inefficient,
and (2) the biological activities of such
platelets have not been well tested or
compared to standard donor platelets.
Previous efforts to optimize Mk yield
from PSCs have had limited success (Lu
et al., 2011; Takayama et al., 2008). In the
current study, Nakamura et al. (2014)
developed a novel approach based on
their prior observation that overexpression
of the MYC proto-oncogene via retroviral
transduction expands PSC-derived Mk
progenitors (Takayama et al., 2010). They
hypothesized that subsequent suppres-
sion of the MYC transgene would trigger
maturation of the expanded Mks withplatelet release. To test this, the authors
used a doxycycline-regulated promoter
to express a chimeric version of MYC
fused to a ligand-dependent destabiliza-
tion domain whose activity is blocked by
the small molecule Shield-1 (Banaszynski
et al., 2006). Thus, addition of doxycycline
and Shield-1 enhanced MYC expression,
while removal of these drugs produced
the opposite effect, allowing for precise
control of MYC protein levels. The authors
combined this strategy with doxycycline-
regulated coexpression of BMI1, a poly-
combcomplexcomponent, that represses
MYC-regulated apoptotic factors INK4A/
ARF (Oguro et al., 2006). This combination
of ectopically expressed transcription fac-
tors stimulated Mk precursor proliferation
for up to 8 weeks with terminal differentia-
tion and platelet release ensuing after
withdrawal of doxycycline and Shield-1.
To suppress cell death associated with
caspase activation, the authors coex-
pressed the anti-apoptotic protein BCL-
XL along with doxycycline-regulated
MYC and BMI1. Two resultant clones,
described as immortalized Mk cell lines
(imMKCL), exhibited increased longevity
with continuous expansion in culture for
up to 20 weeks.
Upon suppression of the immortalizing
genes under standard culture conditions,
imMKCs matured into Mks that released
platelet-like particles resembling endoge-
nous platelets in many respects, including
in ultrastructure, surface antigen expres-
sion, activation upon exposure to the
agonist thrombin, and binding to immobi-
lized vonWillebrand factor in a flow cham-
ber system. Moreover, imMKCL-derived
platelets bound laser-injured blood vessel
walls and contributed to blood clots afterCell Stem Ceintravenous injection into immunodefi-
cient mice that were irradiated to reduce
endogenous platelet counts. Of particular
importance for producing large numbers
of standardized cells for clinical applica-
tions, imMKCLs could be cryopreserved
and then reestablished with retained pro-
liferation and differentiation potential.
Overall, this study advances the field by
showing that carefully titrated, reversible
modulation of transcriptional pathways
can arrest PSC-derived Mk progenitors
for expansion and subsequent manipula-
tion to form platelets. Potential medical
applications include use of human PSC-
derived platelets to treat thrombocyto-
penia and engineering these platelets to
deliver bioactive proteins to sites of blood
vessel injury for enhancing or inhibiting
clot formation (Neyman et al., 2008).
Like all interesting studies, this one
identifies new future challenges; in this
instance, they’re related to optimizing the
yield and quality of imMKCL-derived
platelets for clinical utility. For example,
the imMKCLs released 3–10 platelets per
cell, which is similar to reported yields
from human-PSC-derived Mks (Lu et al.,
2011), but this is in sharp contrast to
normal endogenous Mks, which release
2,000–10,000 platelets in vivo (Kaufman
et al., 1965). The authors calculate that
imMKCLs cultured according to current
methods could theoretically generate
1011 platelets (one donor unit) within
5 days with 25–50 l of medium. This repre-
sents a major advance in PSC-derived
platelet yields, but it remains prohibitively
expensive compared to the cost of human
donor platelets. Moreover, the imMKCL-
derived platelets were predominantly
smaller, contained fewer granules, andll 14, April 3, 2014 ª2014 Elsevier Inc. 425
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and reduced response to agonists in vitro
compared to normal donor-derived plate-
lets. These differences may reflect aber-
rant megakaryopoiesis caused by ectopic
expression ofMYC, BMI1, andBCL-XL, or
alternatively, they may be intrinsic to the
embryonic nature of PSC-derived Mks/
platelets, which exhibit distinct properties
compared to those formed postnatally
(Tober et al., 2007). Thus, innovative
new in vitro differentiation strategies for
PSCs that more accurately reproduce
adult-bone-marrow-type hematopoiesis
may enhance the yield and functionality
of Mk/platelet progeny. Additionally, cul-
ture adaptations tomore closely resemble
the hydrodynamic conditions and cellular
microenvironment of normal Mks may
improve the quantity and quality of
imMKCL-derived platelets. In this regard,
an in vitro microfluidic system described
by their group (Nakagawa et al., 2013)
may be useful.426 Cell Stem Cell 14, April 3, 2014 ª2014 ElIn conclusion, the current study by
Nakamura et al. represents an impor-
tant advance toward generating large
numbers of PSC-derived platelets and
creates a new standard to judge future
approaches. The next major challenge
for supplanting human-donor-derived
platelets with those synthesized ex vivo
are to improve yields even further and
generate a product whose intrinsic prop-
erties—including size, life span, reactivity,
and hemostatic properties—more closely
resemble those of the cells that wewish to
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